Psychiatry

In an interview with HCPLive, Daniel Karlin, MD, discussed how their phase 2B trial demonstrated MM120’s durability through week 12 for the treatment of generalized anxiety disorder.

Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.

A new study found women (1.64) had a greater hazard ratio of depression for CVD than men (1.39).

Acadia Pharmaceuticals decided to stop conducting further clinical trials with pimavanserin for negative symptoms of negative due to topline results.

In an interview with HCPLive, Viktoriya Karakcheyeva, MD, discussed how women healthcare workers experience more burnout than their male colleagues.

A study found a 1-percentage point increase in the population with medical debt was associated with 18.3 more physically unhealthy days and 17.9 more mentally unhealthy days per 1000 people for 30 days.

This psychiatry month in review spotlights new research on detecting and treating major depressive disorder with AI, FDA’s Complete Response Letter for roluperidone, and more.

A new study found menopausal hormone therapy was associated with a significant reduction in depressive symptoms over time with a greater reduction combined with antidepressants.

People experiencing homelessness exhibit similar rates of morbidity compared with housed patients, but a longer adjusted length of hospital stay.

Cancer patients with behavioral health disorders, such as substance abuse, eating disorders, and sleep disorders have a 7.76% increase in health care costs, a new study found.

Minerva Neurosciences announced the receipt of a Complete Response Letter for roluperidone in treatment of negative symptoms in patients with schizophrenia on February 27, 2024 despite clinical trial data indicating improved Negative Symptom Factor Scores and Personal and Social Performance scale scores.

A new study found female teens and young adults were more likely to have an increased antidepressant dispensing rate during the pandemic than male peers.

Check your knowledge on the American Psychiatric Association 2023 practice guideline for the treatment of patients with eating disorders.

A new study found gender inequality, poor work-life balance, a lack of workplace autonomy, and caregiving responsibilities contribute to women in healthcare professions having more stress than their male colleagues.

Among youth with intellectual disabilities and autism, black children and females are more likely to be placed in foster care, a new study found.

A new study found crisis response planning for PTSD among military veterans had lower onset of suicidal ideation than veterans with self-guided safety planning.

A new study found engaging the amygdala can help with memory recall for individuals with depression—and familiar scents helped more than word cues. Memories with odor cues were more arousing and vivid.

A secondary analysis found a brain scan with an AI algorithm predicted within a week 1/3 of patients would respond to sertraline and 2/3 would not.

Telehealth appointments, patients who prefer speaking non-English, older adults, and patients on Medicaid had lower odds of having a depression screening during the early COVID-19 pandemic.

In an interview with HCPLive, Leesha Ellis-Cox, MD, MPH, broke down factors contributing to the bipolar disorder diagnosis gap for African Americans.

According to a new study, overall outpatient mental health care increased from 11.2% to 12.4% between 2018 and 2018. However, for individuals with serious psychological distress, the rate of care decreased from 46.5% to 40.4%.

A study found adolescents with PCOS have a 5.38-fold increased risk for a suicide attempt, and adults have an 8.75-fold increased risk.

A study found 27.5% of individuals who had an emergency department for cannabis use were diagnosed with a new anxiety disorder within 3 years. However, only 5.6% of the general population developed a new anxiety disorder.

A new study found patients with schizophrenia on lurasidone had an effect size change of 0.33 on the PANSS prosocial subscale, suggesting improvements in social functioning.

A pooled analysis showed patients on cariprazine for major depressive disorder had only mild to moderate treatment-emergent adverse events.